Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

High demand for weight-loss and diabetes drugs like Ozempic and Wegovy has led to a shortage in manufacturing. In the ...

In 2025, everyone enrolled in Part D will have their annual out-of-pocket drug costs capped at $2,000. In future years, that cap will rise in step with the rate of change in Part D costs.

On World Alzheimer's Day, we examine how a timely diagnosis can prepare someone with early dementia, and the pros and cons of ...

A U.S. appeals court revived a lawsuit on Friday by healthcare and drug industry groups challenging the first-ever U.S. law ...

Developing advanced drug screening tools is crucial for the advancement of personalized medicine and the creation of more effective treatments. One organ receiving particular attention in this area is ...

Unless officials take action to develop new medications, drug-resistant infections could kill nearly 2 million people a year ...

A Columbia University-led multicenter research effort called IndiPHARM: individual metabolome and exposome assessment for pharmaceutical optimization will develop a platform and monitoring system to ...

The market for weight-loss treatments is expected to see 16 new drugs vying for a slice of the lucrative business currently ...

New machine learning techniques plumb vast "data lakes" to help researchers design faster, cheaper, more effective clinical ...

Shilpa Medicare (SML) climbed 6.12% to Rs 811.25 after the company announced that it has submitted new drug application (NDA) to U.S. Food and Drug Administration (USFDA) for Oxylanthanum Carbonate.

today announced an update for its New Drug Application for Ketamine from the U.S. Food and Drug Administration (the “FDA”) with an assigned a Generic Drug User Fee Amendments of 2022 (“GDUFA ...